Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Clear all
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Interventions
Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
Biological
Lead sponsor
T-MAXIMUM Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer, Recurrent Tumor, Glioblastoma Multiforme, Recurring Glioblastoma, Brain and Central Nervous System Tumors, Glioma, Glioblastomas, Grade IV Astrocytoma, GBM, Recurrent Glioma (Glioblastoma Multiforme), High Grade Glioma, Glioma, Malignant, Brain Cancer
Interventions
LMP744, Conventional Surgery or Biopsy
Drug · Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM, Astrocytoma, Astrocytoma, IDH-Mutant
Interventions
Eflornithine (Dose Level -1), Eflornithine (Dose Level 2), Temozolomide
Drug
Lead sponsor
Orbus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Detroit, Michigan • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
MT-125
Drug
Lead sponsor
Myosin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced May 21, 2026, 5:37 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Glioblastoma, Adult-type Diffuse Gliomas
Interventions
Pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
32
States / cities
Beverly Hills, California • Duarte, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced May 21, 2026, 5:37 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme (GBM), Grade 3 Isocitrate Dehydrogenase (IDH) Wildtype Astrocytoma, Grade 3 or 4 Astrocytoma, Glioblastoma Surgery
Interventions
Icapamespib
Drug
Lead sponsor
Samus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Los Angeles, California • San Diego, California • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Early Phase 1 Interventional
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Interventions
Troriluzole
Drug
Lead sponsor
Ugonma Chukwueke
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
Interventions
Debio 0123, Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Chicago, Illinois • New York, New York • Dallas, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
Interventions
Balstilimab, Botensilimab, Liposomal Doxorubicin, Sonocloud-9 (SC-9)
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 21, 2026, 5:37 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 5:37 PM EDT